רייאטאז 200 מג
bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.
רייאטאז 300 מג
bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir
אטאזנביר טבע 150 מג
teva israel ltd - atazanavir as sulfate - קפסולות - atazanavir as sulfate 150 mg - atazanavir
אטאזנביר טבע 200 מג
teva israel ltd - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir
אטאזנביר טבע 300 מג
teva israel ltd - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir
רייאטאז 150 מ"ג
bristol, myers squibb (israel) limited - atazanavir as sulfate 150 mg - capsules - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.
סאנלנקה טבליות מצופות
gilead sciences israel ltd - lenacapavir as sodium - טבליות מצופות פילם - lenacapavir as sodium 300 mg - lenacapavir
סאנלנקה תמיסה להזרקה
gilead sciences israel ltd - lenacapavir as sodium - תמיסה להזרקה - lenacapavir as sodium 309 mg/ml - lenacapavir
קונטרולוק 40
takeda israel ltd - pantoprazole - טבליה - pantoprazole 40 mg - pantoprazole - pantoprazole - short term treatment of acute duodenal ulcer. acute gastric ulcer. moderate and severe reflux esophagitis. eradication of helicobacter pylori in combination with clarithromycin and amoxycillin or clarithromycin and metronidazole or amoxycillin and metronidazole in cases of duodenal ulcer and gastric ulcer with the objective of reducing of duodenal and gastric ulcers caused by this microorganism. zollinger ellison syndrome.
קונטרולוק 20 מג
takeda israel ltd - pantoprazole - טבליה - pantoprazole 20 mg - pantoprazole - pantoprazole - treatment of reflux oesophagitis and associated symptoms (e.g. hearburn acid regurgitation pain on swallowing) . for long-term management and prevention of relapse in reflux oesophagitis. prevention of gastroduodenal ulcers induced by non-steroidal anti-inflammatory drugs (nsaids) in patients at risk with a need for continuous nsaids treatment.